Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Net Margin (2017 - 2026)

Akebia Therapeutics has reported Net Margin over the past 9 years, most recently at 21.25% for Q4 2025.

  • Quarterly Net Margin rose 2780.0% to 21.25% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 2.26% through Dec 2025, up 4107.0% year-over-year, with the annual reading at 2.26% for FY2025, 4107.0% up from the prior year.
  • Net Margin was 21.25% for Q4 2025 at Akebia Therapeutics, down from 0.92% in the prior quarter.
  • Over five years, Net Margin peaked at 46.31% in Q4 2021 and troughed at 156.93% in Q2 2021.
  • The 5-year median for Net Margin is 27.85% (2023), against an average of 46.3%.
  • The largest YoY upside for Net Margin was 30172bps in 2021 against a maximum downside of -6468bps in 2021.
  • A 5-year view of Net Margin shows it stood at 46.31% in 2021, then crashed by -125bps to 11.66% in 2022, then surged by 109bps to 1.09% in 2023, then crashed by -4589bps to 49.04% in 2024, then skyrocketed by 57bps to 21.25% in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Net Margin are 21.25% (Q4 2025), 0.92% (Q3 2025), and 0.4% (Q2 2025).